Compare NP & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NP | TARS |
|---|---|---|
| Founded | 2017 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.6B |
| IPO Year | 2025 | 2020 |
| Metric | NP | TARS |
|---|---|---|
| Price | $28.21 | $68.26 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 10 |
| Target Price | $34.00 | ★ $99.80 |
| AVG Volume (30 Days) | 471.5K | ★ 652.8K |
| Earning Date | 10-20-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 48.21 |
| EPS | ★ 0.28 | N/A |
| Revenue | N/A | ★ $451,360,000.00 |
| Revenue This Year | $26.63 | $61.17 |
| Revenue Next Year | $17.59 | $26.47 |
| P/E Ratio | $180.44 | ★ N/A |
| Revenue Growth | N/A | ★ 146.71 |
| 52 Week Low | $14.78 | $53.89 |
| 52 Week High | $35.15 | $91.53 |
| Indicator | NP | TARS |
|---|---|---|
| Relative Strength Index (RSI) | 43.02 | 39.23 |
| Support Level | $26.86 | $60.95 |
| Resistance Level | $29.01 | $74.51 |
| Average True Range (ATR) | 1.03 | 3.34 |
| MACD | 0.14 | -0.37 |
| Stochastic Oscillator | 37.29 | 2.22 |
Neptune Insurance Holdings Inc is a high-growth, profitable, data-driven MGA that offers residential and commercial insurance products, including primary flood insurance, excess flood insurance and parametric earthquake insurance, distributed through a nationwide network of agencies in the United States. The company underwrites and administers the issuance of insurance policies on behalf of a diverse panel of insurance and reinsurance companies and does not take any balance sheet insurance risk or have claims handling responsibility relating to the policies it sells.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.